EUVIMEDEUVIMED entdecken
Open Access

Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease

Jack P Gleeson iD, Andrea Knezevic iD, Maria Bromberg, Sujata Patil iD, Joel Sheinfeld, Brett S Carver iD, Manjit Bains, David R Jones iD, Dean F Bajorin iD, George J Bosl iD, Deaglan J McHugh iD, Samuel A Funt iD und 2 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.02542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Jack P Gleeson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Ifosfamide, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP. PATIENTS AND METHODS Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable response (complete response or partial response with negative tumor markers), overall survival (OS) and progression-free survival (PFS) rates, relapse, and toxicity were determined. Disease was reclassified according to the International Prognostic Factor Study Group (IPFSG) score. RESULTS Of the 104 patients, 87 had favorable risk factors and 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Ten patients were treated for a second gonadal primary GCT. With a median follow-up of 8.9 years, the 5-year PFS and OS rates were 66% (95% CI, 55 to 74) and 69% (95% CI, 59 to 77), respectively. Among 87 patients with favorable-risk disease, 69 (79%) achieved a favorable response with 5-year PFS and OS rates of 67% (95% CI, 56 to 76) and 72% (95% CI, 61 to 80), respectively. Among 17 patients with MSKCC unfavorable-risk disease, 13 (76%) achieved a favorable response with 5-year PFS and OS rates of 59% (95% CI, 33 to 78) and 56% (95% CI, 28 to 76), respectively. After IPFSG reclassification, 5-year PFS and OS rates for patients with ≤intermediate-risk disease were 75% (95% CI, 50 to 89) and 73% (95% CI, 55 to 85), respectively. CONCLUSION TIP is an effective second-line regimen for patients with GCT. Similar outcomes were observed in patients with favorable- and unfavorable-risk disease. The randomized TIGER trial (ClinicalTrials.gov identifier: NCT02375204 ) comparing TIP with high-dose chemotherapy will determine the optimal second-line treatment approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCisplatinIfosfamideNeoplasms, Germ Cell and EmbryonalPaclitaxelSalvage TherapyAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultFollow-Up StudiesTreatment OutcomeClinical Trials as Topic

Substanzen

CisplatinIfosfamidePaclitaxel

Autor:innen und Institutionen

  • Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland.
  • Medical Oncology Department, Cork University Hospital, Cork, Ireland.
  • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
  • Weill Cornell Medical College, New York, NY.

ORCID-Profile: Jack P Gleeson, Andrea Knezevic, Sujata Patil, Brett S Carver, David R Jones, Dean F Bajorin, George J Bosl, Deaglan J McHugh, Samuel A Funt, Robert J Motzer, Darren R Feldman

Förderung

  • NCI NIH HHS

Zitieren

APA

Gleeson, J. P., Knezevic, A., Bromberg, M., Patil, S., Sheinfeld, J., Carver, B. S., Bains, M., Jones, D. R., Bajorin, D. F., Bosl, G. J., McHugh, D. J., Funt, S. A., Motzer, R. J., & Feldman, D. R. (2024). Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02542

Vancouver

Gleeson JP, Knezevic A, Bromberg M, Patil S, Sheinfeld J, Carver BS, et al. Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02542

BibTeX
@article{Gleeson2024,
  author = {Gleeson, Jack P and Knezevic, Andrea and Bromberg, Maria and Patil, Sujata and Sheinfeld, Joel and Carver, Brett S and Bains, Manjit and Jones, David R and Bajorin, Dean F and Bosl, George J and McHugh, Deaglan J and Funt, Samuel A and Motzer, Robert J and Feldman, Darren R},
  title = {Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.02542}
}
Kostenlos starten →